Oncogenic protein interfaces: small molecules, big challenges
The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.
Abstract
Historically, targeting protein-protein interactions with small molecules was not thought possible because the corresponding interfaces were considered mostly flat and featureless and therefore 'undruggable'. Instead, such interactions were targeted with larger molecules, such as peptides and antibodies. However, the past decade has seen encouraging breakthroughs through the refinement of existing techniques and the development of new ones, together with the identification and exploitation of unexpected aspects of protein-protein interaction surfaces. In this Review, we describe some of the latest techniques to discover modulators of protein-protein interactions and how current drug discovery approaches have been adapted to successfully target these interfaces.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Protein–protein interactions (PPIs) play a crucial role in numerous biological processes, including signal transduction, cell proliferation, growth, differentiation, apoptosis.303–305”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [305]
In the citing paper
“However, their suitability for tight and narrow PPI interfaces and poor selectivity limits their application in targeting PPIs.305”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [305]
In the citing paper
“PPIs have relatively large and amorphous interfaces, rather than small and well-defined crevices.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [22]
In the citing paper
“Compared with targeting enzymes or receptors, however, the development of molecules targeting PPIs has been challenging [22–24].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [22]
Citations
Cites
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex
de Vos, A. M., Ultsch, M., & Kossiakoff, A. A. (1992) · Science · doi:10.1126/science.1549776 · Cited by 2,239
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Research works printed but not linked: 1
- Ratnaparkhi, M. P., Chaudhari, S. P. & Pandya, V. A. Peptides and proteins in pharmaceuticals. Int. J. Curr. Pharm. Res. 3, 1–9 (2011).
Cited by
Items 101–200 of 319
Somsen, B. A., Cossar, P. J., Arkin, M. R., Brunsveld, L., & Ottmann, C. (2024) · ChemBioChem · doi:10.1002/cbic.202400214 · Cited by 41
Sammak, S., & Zinzalla, G. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.06.004 · Cited by 43
Oo, C., & Kalbag, S. S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1160778 · Cited by 36
Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives
Bhardwaj, V., Tan, Y. Q., Wu, M., Ma, L., Zhu, T., Lobie, P. E., & Pandey, V. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.042 · Cited by 40
Smith, E. W., Nevins, A. M., Qiao, Z., Liu, Y., Getschman, A. E., Vankayala, S. L., Kemp, M. T., Peterson, F. C., Li, R., Volkman, B. F., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b02042 · Cited by 35
Stapled peptides as a new technology to investigate protein–protein interactions in human platelets
Iegre, J., Ahmed, N. S., Gaynord, J. S., Wu, Y., Herlihy, K. M., Tan, Y. S., Pires, M. E. L., Jha, R., Lau, Y. H., Sore, H. F., et al. (2018) · Chemical Science · doi:10.1039/c8sc00284c · Cited by 40
Targeting MYC: From understanding its biology to drug discovery
Ross, J., Miron, C. E., Plescia, J., LaPlante, P., McBride, K. M., Moitessier, N., & Möröy, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113137 · Cited by 36
Camps-Fajol, C., Cavero, D., Minguillón, J., & Surrallés, J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107544 · Cited by 36
Chae, H., Kwak, D., Lee, M., Chi, S., & Kim, K. B. (2018) · Nanoscale · doi:10.1039/c8nr06423g · Cited by 35
Du, Q., Qian, Y., & Xue, W. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00029 · Cited by 36
“In recent years, development of small molecule modulators targeting protein–protein interactions (PPIs) has emerged as a promising therapeutic intervention in complex diseases (Nero et al., 2014; Nim et al., 2016; Weng et al., 2019).”
BackgroundIdentification of small molecule inhibitors of the Aurora-A/TPX2 complex
Asteriti, I. A., Daidone, F., Colotti, G., Rinaldo, S., Lavia, P., Guarguaglini, G., & Paiardini, A. (2017) · Oncotarget · doi:10.18632/oncotarget.16738 · Cited by 34
“However, recent successful examples have questioned this view, and inhibitors of specific interactions have now reached clinical trials for anti-cancer therapy [27].”
BackgroundLee, H.-W., Choi, B., Kang, H. N., Kim, H., Min, A., Cha, M., Ryu, J. Y., Park, S., Sohn, J., Shin, K., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0212-3 · Cited by 35
Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
Koach, J., Holien, J. K., Massudi, H., Carter, D. R., Ciampa, O. C., Herath, M., Lim, T., Seneviratne, J. A., Milazzo, G., Murray, J. E., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1112 · Cited by 34
“Protein–protein interaction sites involving oncoproteins have become a major focus for the discovery of cancer therapeutics, whereby oncogenic signal activation or oncoprotein stability can be inhibited by competitive binding of small molecules at these protein–protein interfaces (5).”
BackgroundSelf-citationMapping oncogenic protein interactions for precision medicine
Tabar, M. S., Francis, H., Yeo, D., Bailey, C. G., & Rasko, J. E. J. (2022) · International Journal of Cancer · doi:10.1002/ijc.33954 · Cited by 30
“Strategies to identify and validate lead compounds to target PPI interfaces have been reviewed extensively elsewhere.(17,22,143) Hence, we briefly discuss three major platforms here.”
BackgroundRaffeiner, P., Röck, R., Schraffl, A., Hartl, M., Hart, J. R., Janda, K. D., Vogt, P. K., Stefan, E., & Bister, K. (2014) · Oncotarget · doi:10.18632/oncotarget.2588 · Cited by 33
“PPIs are challenging targets for small-molecule inhibitors [14, 40], although there are examples of PPI inhibitors in the clinic [41-43].”
Loh, J. K., Asad, N., Samarakoon, T. B., & Hanson, P. R. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b01429 · Cited by 31
Discovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction
Sun, H., Wang, J., Liu, S., Zhou, X., Dai, L. X., Chen, C., Xu, Q., Wen, X., Cheng, K., Sun, H., et al. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00521 · Cited by 30
Are fibrinaloid microclots a cause of autoimmunity in Long Covid and other post-infection diseases?
Kell, D. B., & Pretorius, E. (2023) · Biochemical Journal · doi:10.1042/bcj20230241 · Cited by 34
Screening-based approaches to identify small molecules that inhibit protein–protein interactions
Choi, S., & Choi, K.-Y. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1280456 · Cited by 29
“Recent studies have shown that small molecules, which can be defined as low molecular weight organic compounds with fewer than 900 daltons, are potential candidates for PPI inhibition [19-24].”
BackgroundApplication of Negative Design To Design a More Desirable Virtual Screening Library
Yang, Z., He, J.-H., Lü, A., Hou, T., & Cao, D. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01476 · Cited by 33
Inhibition of β-catenin and STAT3 with a curcumin analog suppresses gastric carcinogenesis in vivo
Uehara, Y., Inoue, M., Fukuda, K., Yamakoshi, H., Hosoi, Y., Kanda, H., Oshima, M., Iwabuchi, Y., & Shibata, H. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0434-3 · Cited by 27
“effects of CD44 inhibition in cancer therapy remain controversial, numerous reports have shown effective reduction of malignancies, including colon, mammary, and ovarian cancers, following treatment with CD44 inhibitors [40].”
BackgroundYeh, J., Kreimer, S. D., Walker, S. R., Emori, M. M., Krystal, H. L., Richardson, A. L., Ivanov, A. R., & Frank, D. A. (2015) · Genes & Cancer · doi:10.18632/genesandcancer.58 · Cited by 27
“However, unlike kinases which have well-defined ATP binding pockets in which small molecules can be designed to fit, transcription factors have large surface areas for protein-DNA and protein-protein interactions which are more difficult to target [15].”
BackgroundZhou, Y., Zhang, N., Chen, W., Zhao, L., & Zhong, R. (2016) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp06276d · Cited by 27
Sun, J., Xu, M., Ru, J., James-Bott, A., Xiong, D., Wang, X., & Cribbs, A. P. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115500 · Cited by 27
Wu, Y., Olsen, L. B., Lau, Y. H., Jensen, C. H., Rossmann, M., Baker, Y. R., Sore, H. F., Collins, S., & Spring, D. R. (2016) · ChemBioChem · doi:10.1002/cbic.201500648 · Cited by 32
Stapled Peptides: Providing the Best of Both Worlds in Drug Development
Xie, X., Gao, L., Shull, A. Y., & Teng, Y. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0102 · Cited by 30
Chitosan Nanoparticles for miRNA Delivery
Denizli, M., Aslan, B., Mangala, L. S., Jiang, D., Rodriguez‐Aguayo, C., Lopez‐Berestein, G., & Sood, A. K. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7138-1_14 · Cited by 26
Borsatto, A., Gianquinto, E., Rizzi, V., & Gervasio, F. L. (2024) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c01318 · Cited by 34
Zhang, Z., Zhao, L., Wang, J., & Wang, C. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3384238 · Cited by 31
“On the one hand, the general properties of large, flat, and featureless of PPI interfaces make existing compound librariesforscreeningconventionaltargetsunsuitableforscreen-ingPPIMs[7],[8].”
BackgroundProgranulin sustains STAT 3 hyper‐activation and oncogenic function in colorectal cancer cells
Laudisi, F., Cherubini, F., Grazia, A. D., Dinallo, V., Fusco, D. D., Franzè, E., Ortenzi, A., Salvatori, I., Scaricamazza, S., Monteleone, I., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12552 · Cited by 27
“, 2012), STAT3 inhibitors can enhance the risk of infections (Nero et al., 2014).”
BackgroundLMPID: A manually curated database of linear motifs mediating protein–protein interactions
Sarkar, D., Jana, T., & Saha, S. (2015) · Database · doi:10.1093/database/bav014 · Cited by 24
Danelius, E., Pettersson, M., Bred, M., Min, J., Waddell, M. B., Guy, R. K., Grøtli, M., & Erdélyi, M. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01510g · Cited by 25
Takaoka, Y., Nagumo, K., Azizah, I. N., Oura, S., Iwahashi, M., Kato, N., & Ueda, M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006639 · Cited by 26
“FA has been widely used for the quantitative and highthroughput screening (HTS) of PPI inducers or inhibitors (14, 15), and by applying it to the assay system for COI1–JAZ co-receptors, quantitative analyses of the affinity values of endogenous JA derivatives covering almost all the combinations of COI1–JAZ co-recepto…”
MethodStructure-Function Analysis of the Mcl-1 Protein Identifies a Novel Senescence-regulating Domain
Demelash, A., Pfannenstiel, L. W., Tannenbaum, C. S., Li, X., Kalady, M. F., DeVecchio, J., & Gastman, B. R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.663898 · Cited by 27
“Although this form of therapy may have direct clinical applicability, it can also be used to design other effective small-molecule inhibitors, a strategy already having clinical success in some cancers (46).”
BackgroundTargeting kinase signaling pathways with constrained peptide scaffolds
Hanold, L. E., Fulton, M. D., & Kennedy, E. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.014 · Cited by 24
Truong, J. Q., George, A., & Holien, J. K. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00213a · Cited by 27
Self-citationBennett, R. P., Salter, J. D., & Smith, H. C. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.03.004 · Cited by 24
“Twelve small-molecule therapeutics are in clinical development; these target various PPI-involved cancer pathways and include drugs targeting disruption of protein pairs such as MDM2-p53, tubulin a and tubulin b, BCL-2 family-BH3 domain, and IAP family-SMAC [55].”
BackgroundPeptide‐Based Inhibitors for SARS‐CoV‐2 and SARS‐CoV
Panchal, D., Kataria, J., Patel, K., Crowe, K. M., Pai, V., Azizogli, A., Kadian, N., Sanyal, S., Roy, A., Dodd‐o, J., et al. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100104 · Cited by 23
The rational discovery of multipurpose inhibitors of the ornithine decarboxylase
Chai, X., Zhan, J., Pan, J., He, M., Li, B., Wang, J., Ma, H., Wang, Y., & Liu, S. (2020) · The FASEB Journal · doi:10.1096/fj.202001222r · Cited by 22
Fragment-based drug discovery and protein–protein interactions
Turnbull, A. P., Boyd, S., & Walse, B. (2014) · Research and Reports in Biochemistry · doi:10.2147/rrbc.s28428 · Cited by 29
Diversity-Oriented Synthesis of a Library of Star-Shaped 2H-Imidazolines
Yu, X., Guttenberger, N., Fuchs, E., Peters, M., Weber, H., & Breinbauer, R. (2015) · ACS Combinatorial Science · doi:10.1021/acscombsci.5b00107 · Cited by 22
Natale, C. D., Celetti, G., Scognamiglio, P. L., Cosenza, C., Battista, E., Causa, F., & Netti, P. A. (2018) · Chemical Communications · doi:10.1039/c8cc04943b · Cited by 21
Lan, L., Liu, J., Xing, M., Smith, A. R., Wang, J., Wu, X., Appelman, C., Li, K., Roy, A., Gowthaman, R., et al. (2020) · Cancers · doi:10.3390/cancers12082221 · Cited by 21
“Targeting protein–protein interaction has yielded a list of small molecule compounds that are in clinical trials or in the clinic [39], while inhibitors of protein–RNA/DNA interaction are somewhat new.”
BackgroundHu, G., Paola, L. D., Liang, Z. T., & Giuliani, A. (2017) · BioMed Research International · doi:10.1155/2017/2483264 · Cited by 20
“The study of protein complexes not only elucidates the molecular mechanism of many diseases [3] but also provides structural information of proteinprotein interactions [4].”
BackgroundSingh, N., Chaput, L., & Villoutreix, B. O. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00545 · Cited by 21
Hain, A. U. P., Miller, A. S., Levitskaya, J., & Bosch, J. (2016) · ChemMedChem · doi:10.1002/cmdc.201500515 · Cited by 22
Zhou, R., Chen, J., Jia, J., Xu, Y., Ye, Y., 钟国平, Chen, T., & Qiu, L. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05776-2 · Cited by 23
“Accumulating evidence revealed that degradation of oncoproteins may contribute to countering the almost inevitable drug resistance due to target inhibition, and increase the peptide presentation capability of MHC molecules which synergize with cancer immunotherapy [5, 7], implying that targeting E3s may provide a prom…”
BackgroundTrisciuzzi, D., Villoutreix, B. O., Siragusa, L., Baroni, M., Cruciani, G., & Nicolotti, O. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2218641 · Cited by 22
“It has also been suggested that, at least for the time being, hydrophobic helix-grooves PPIs appear to be easier modulated with small molecules compared to other types of interfaces [3].”
BackgroundDARC 2.0: Improved Docking and Virtual Screening at Protein Interaction Sites
Gowthaman, R., Lyskov, S., & Karanicolas, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131612 · Cited by 20
“Whereas almost all drugs currently in the clinic inhibit one of several “traditional” target classes (G protein-coupled receptors, enzymes, nuclear receptors, transporters, and ion channels) [13, 14], protein-protein interactions now stand among a broad new emerging class of “non-traditional” targets [15, 16].”
BackgroundJana, T., Ghosh, A., Mandal, S. D., Banerjee, R., & Saha, S. (2017) · Royal Society Open Science · doi:10.1098/rsos.160501 · Cited by 19
Targeting protein self-association in drug design
Thabault, L., Liberelle, M., & Frédérick, R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.028 · Cited by 19
He, X., Huang, N., Qiu, Y., Zhang, J., Liu, Y., Yin, X., & Lu, S. (2021) · Molecules · doi:10.3390/molecules26040962 · Cited by 19
“Protein‐protein interactions (PPIs) modulates a good deal of a biologi‐ cal process including cell invasion and adaption [3].”
BackgroundTon, A.-T., Foo, J., Singh, K., Lee, J., Kalyta, A., Morin, H., Perez, C., Ban, F., Leblanc, E., Lallous, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052588 · Cited by 17
“Consequently, integrating novel CADD approaches would play an important role in targeting novel sites without classical properties, such as those with unusual and convex pocket shapes or transient protein–protein interactions [28].”
BackgroundApplying Spatiotemporal Modeling of Cell Dynamics to Accelerate Drug Development
Chen, X., Xu, S., Chu, B., Guo, J., Zhang, H.-K., Sun, S.-Y., Song, L., & Feng, X. (2024) · ACS Nano · doi:10.1021/acsnano.4c12599 · Cited by 19
Application of Nanopore Sensors for Biomolecular Interactions and Drug Discovery
Jeong, K., Kim, J., Dhanasekar, N. N., Lee, M., & Chi, S. (2022) · Chemistry - An Asian Journal · doi:10.1002/asia.202200679 · Cited by 18
Inhibition of Amyloid Protein Aggregation Using Selected Peptidomimetics
Maity, D. (2022) · ChemMedChem · doi:10.1002/cmdc.202200499 · Cited by 20
Aboalhaija, N. H., Zihlif, M., & Taha, M. O. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.03.006 · Cited by 17
Catalano, M., Oehler, S., Prati, L., Favalli, N., Bassi, G., Scheuermann, J., & Neri, D. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c02304 · Cited by 18
Noncellular screening for the discovery of protein–protein interaction modulators
Kieffer, C., Jourdan, J., Jouanne, M., & Voisin‐Chiret, A. S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.012 · Cited by 20
Dailing, A., Luchini, A., & Liotta, L. A. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1079487 · Cited by 16
“Even with all the modeling and computational methods available, only 0.5% of protein–protein complexes have been revealed and made available to the public via the Protein Data Bank [5].”
BackgroundInfluentialChen, B., Liu, C., Cong, W., Gao, F., Zou, Y., Su, L., Liu, L., Hillisch, A., Lehmann, L. E., Bierer, D. E., et al. (2023) · Chemical Science · doi:10.1039/d3sc04279k · Cited by 16
Interface-aware molecular generative framework for protein–protein interaction modulators
Wang, J., Mao, J., Li, C., Xiang, H., Wang, X., Wang, S., Wang, Z., Chen, Y., Li, Y., No, K. T., et al. (2024) · Journal of Cheminformatics · doi:10.1186/s13321-024-00930-0 · Cited by 19
“Despite considerable efforts, developing modulators of PPI targets, particularly those targeting PPI interfaces, remains challenging [6, 8 – 12].”
Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors
Kanthala, S., Pallerla, S., & Jois, S. D. S. (2015) · Future Oncology · doi:10.2217/fon.14.312 · Cited by 17
Smart applications of bionanosensors for BCR/ABL fusion gene detection in leukemia
Avelino, K. Y. P. S., Silva, R. R., da Silva, A. G., Oliveira, M. D. L., & Andrade, C. A. S. (2017) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2017.08.002 · Cited by 16
Structural Basis of the Differential Binding of Engineered Knottins to Integrins αVβ3 and α5β1
Agthoven, J. F. V., Shams, H., Cochran, F. V., Alonso, J. L., Kintzing, J. R., Garakani, K., Adair, B. D., Xiong, J.-P., Mofrad, M. R. K., Cochran, J. R., et al. (2019) · Structure · doi:10.1016/j.str.2019.06.011 · Cited by 16
Exploring Ubiquitin-specific proteases as therapeutic targets in Glioblastoma
Samuel, V. P., Moglad, E. H. O., Afzal, M., Kazmi, I. A., Alzarea, S. I., Ali, H., Almujri, S. S., Abida, A., Imran, M., Gupta, G., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155443 · Cited by 15
Beekman, A. M., O'Connell, M. A., & Howell, L. A. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201705008 · Cited by 21
Mapping of Protein-Protein Interactions: Web-Based Resources for Revealing Interactomes
Gemović, B., Šumonja, N., Davidović, R., Perović, V., & Veljković, N. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180214113704 · Cited by 18
Targeting growth hormone in cancer: future perspectives
Wang, Y., Jamieson, S. M. F., & Perry, J. K. (2023) · Endocrine Related Cancer · doi:10.1530/erc-23-0033 · Cited by 15
Stapled peptides: targeting protein-protein interactions in drug development
Zhang, Q., Wang, Z., Mei, X., Chen, Q., & Zhang, C. (2024) · Exploration of Drug Science · doi:10.37349/eds.2024.00041 · Cited by 16
Shedding light on complexity of protein–protein interactions in cancer
Yoon, T., & Lee, H.-W. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.07.001 · Cited by 14
Explore Protein–Protein Interactions for Cancer Target Discovery Using the OncoPPi Portal
Ivanov, A. A. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9873-9_12 · Cited by 16
Peptide Based Inhibitors of Protein Binding to the Mitogen-Activated Protein Kinase Docking Groove
Alexa, A., Ember, O., Szabó, I., Yousef, M., Póti, Á., Reményi, A., & Bánóczi, Z. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.690429 · Cited by 15
“Although there are several successful small molecule inhibitors (Nero et al., 2014; Lu et al., 2020), larger compounds may be better to inhibit PPI’s.”
BackgroundSicking, M., Jung, M., & Lang, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910358 · Cited by 15
Zhang, D., Xiong, L., Fang, L., Li, H., Zhao, X., Luan, R., Zhao, P., & Zhang, X. (2021) · Journal of Separation Science · doi:10.1002/jssc.202100484 · Cited by 13
Barthel, T., Wollenhaupt, J., Lima, G. M. A., Wahl, M. C., & Weiss, M. S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01165 · Cited by 14
Considerations of Protein Subpockets in Fragment‐Based Drug Design
Bartolowits, M. D., & Davisson, V. J. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12631 · Cited by 14
Rational design and screening of peptide-based inhibitors of heat shock factor 1 (HSF1)
Xu, R., Burchfiel, E. T., Dong, B., Rettko, N. J., Dunyak, B. M., Shao, H., Thiele, D. J., & Gestwicki, J. E. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.04.018 · Cited by 14
“Indeed, this task seems quite difficult, as HSF1 has many features of an “undruggable” target, such as a large, flat buried surface area [28].”
BackgroundIdentification of C3b-Binding Small-Molecule Complement Inhibitors Using Cheminformatics
Garcia, B. L., Skaff, D. A., Chatterjee, A., Hanning, A., Walker, J. K., Wyckoff, G. J., & Geisbrecht, B. V. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601932 · Cited by 14
“For instance, by 2014, 12 distinct small-molecule drugs that inhibit protein–protein interactions of various oncogenic targets were in clinical trials or had already reached market (28).”
BackgroundCell-free Biosynthesis of Peptidomimetics
Lee, K., Willi, J. A., Cho, N., Kim, I., Jewett, M. C., & Lee, J. (2023) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-022-0268-5 · Cited by 13
“Second, the selection approach used to discover peptidomimetics from a library mainly relies on the solid binding affinity toward target proteins by protein-protein interaction [4,184-187], which may not necessarily yield an efficient inhibitor of bioactivities.”
Current trends and future prospects of drug repositioning in gastrointestinal oncology
Fatemi, N., Karimpour, M., Bahrami, H., Zali, M. R., Chaleshi, V., Riccio, A., Mojarad, E. N., & Totonchi, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1329244 · Cited by 19
Bergman, M. T., Zhang, W., Liu, Y., Jang, H., & Nussinov, R. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c03243 · Cited by 15
Winter, A., Sigurdardottir, A., DiCara, D. M., Valenti, G., Blundell, T. L., & Gherardi, E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0446 · Cited by 13
“Many essential cellular functions are carried out by multiprotein assemblies, and so it is not surprising that many human diseases, such as neurodegenerative diseases (43) and metabolic diseases (44) as well as cancer (45), can be caused by aberrant PPI.”
BackgroundTEAD–YAP Interaction Inhibitors and MDM2 Binders from DNA‐Encoded Indole‐Focused Ugi Peptidomimetics
Kunig, V. B. K., Potowski, M., Akbarzadeh, M., Škopić, M. K., Smith, D. D. S., Arendt, L., Dormuth, I., Adihou, H., Andlovic, B., Karataş, H., et al. (2020) · Angewandte Chemie · doi:10.1002/ange.202006280 · Cited by 16
Giorgio, C., Russo, S., Incerti, M., Bugatti, A., Vacondio, F., Barocelli, E., Mor, M., Pala, D., Hassan‐Mohamed, I., Gioiello, A., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.10.006 · Cited by 14
Protein–Protein Interface and Disease: Perspective from Biomolecular Networks
Hu, G., Xiao, F., Li, Y., Li, Y., & Vongsangnak, W. (2016) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2016_40 · Cited by 14
Lee, D., Choi, J., Yang, M. J., Park, C., & Seo, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01140 · Cited by 13
Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma
Ye, T., Mishra, A. K., Banday, S., Li, R., Hu, K., Coleman, M. M., Shan, Y., Chowdhury, S., Zhou, L., Pak, M. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114211 · Cited by 13
Recent Developments in 14–3–3 Stabilizers for Regulating Protein–Protein Interactions: An Update
Tian, Y., Li, L., Wu, L., Xu, Q., Li, Y. M., Pan, H., Bing, T., Bai, X., Finko, A. V., Li, Z., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01936 · Cited by 12
Designing a Nitro-Induced Sutured Biomacromolecule to Engineer Electroconductive Adhesive Hydrogels
Baidya, A., Ghovvati, M., Lu, C., Naghsh‐Nilchi, H., & Annabi, N. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c11348 · Cited by 11
Liu, S., Wang, Z., Wu, S., Cao, T., & Zhao, G. (2023) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2023.132704 · Cited by 11
The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function
Kumaraswamy, A., Mamidi, A., Desai, P., Sivagnanam, A., Perumalsamy, L. R., Ramakrishnan, C. V., Gromiha, M. M., Rajalingam, K., & Mahalingam, S. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004452 · Cited by 11
Split-enzyme immunoassay to monitor EGFR-HER2 heterodimerization on cell surfaces
Kim, S. J., Dixon, A. S., & Owen, S. C. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.08.055 · Cited by 11
Unleashing the power of DNA-encoded libraries for challenging targets in drug discovery
Du, N., Li, Y., Lou, Q., Zhang, G., Li, Y., & Li, Y. (2026) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2026.100115 · Cited by 11
DNA-modulated dimerization and oligomerization of cell membrane receptors
Ali, A. A., & You, M. (2024) · Chemical Communications · doi:10.1039/d4cc03077j · Cited by 11
Megalin‐related mechanism of hemolysis‐induced acute kidney injury and the therapeutic strategy
Goto, S., Hosojima, M., Kabasawa, H., Arai, K., Takemoto, K., Aoki, H., Komochi, K., Kobayashi, R., Sugita, N., Endo, T., et al. (2024) · The Journal of Pathology · doi:10.1002/path.6284 · Cited by 11
Bayó‐Puxán, N., Rodríguez‐Mias, R. A., Goldflam, M., Kotev, M. I., Ciudad, S., Hipolito, C. J., Varese, M., Suga, H., Campos‐Olivas, R., Barril, X., et al. (2015) · ChemMedChem · doi:10.1002/cmdc.201500467 · Cited by 13
Lan, T., Su, S., Ping, P., Hutvágner, G., Liu, T., Pan, Y. F., & Li, J. (2024) · Nature Machine Intelligence · doi:10.1038/s42256-024-00803-z · Cited by 14
Neuropeptide Y receptors 1 and 2 as molecular targets in prostate and breast cancer therapy
Tomić, K., Kostevšek, N., Romeo, S., & Bassanini, I. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118117 · Cited by 11
Ge, X., Lee, Y.-T., & Yeh, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1564339 · Cited by 14
Metadata
- Authors
- Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W.
- Affiliations
- Australian Cancer Research Foundation (AU)
- The University of Melbourne (AU)
- Corresponding author
- Parker, Michael W.
- Venue
- Nature Reviews Cancer
- Published
- 2014-03-13
- Volume
- 14
- Issue
- 4
- Pages
- 248-262
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2003516462
- Cited by
- 312
- References
- 161
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 35 · 2023: 29 · 2022: 15 · 2021: 19 · 2020: 29 · 2019: 19 · 2018: 26 · 2017: 24 · 2016: 34 · 2015: 37 · 2014: 15
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, oncoprotein, small molecule modulators, drug discovery, undruggable targets, protein-protein interaction surfaces, cancer drug targets
- MeSH terms
- Animals, Antineoplastic Agents, Binding Sites, Drug Screening Assays, Antitumor, Humans, Neoplasms, Protein Binding, Surface Properties, Oncogene Proteins, Protein Interaction Domains and Motifs, Protein Interaction Maps, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.